Transgene Biotek (BOM:526139) Other Current Receivables: ₹0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526139 Transgene Biotek Ltd BOM:526139
45 GF Score
Price ₹2.93
GF Value ₹6.67
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Other Current Receivables?

Transgene Biotek BOM:526139 -0.34% 45 Other Current Receivables is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 45/100 and a GF Value™ of ₹6.67 (Possible Value Trap). The stock has 4 warning signs investors should review.

Transgene Biotek's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹0.00 Mil.

Transgene Biotek Other Current Receivables Related Terms

Transgene Biotek Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek Other Current Receivables Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:526139
45GF Score
Transgene Biotek Ltd BOM:526139
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹0.00 Mil mean?
Transgene Biotek (BOM:526139) has a Other Current Receivables of ₹0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Transgene Biotek and its competitors.
Is Transgene Biotek's Other Current Receivables too high?
Transgene Biotek's current Other Current Receivables is ₹0.00 Mil. Overall, Transgene Biotek has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's Other Current Receivables compare to VRTX and REGN?
Transgene Biotek's Other Current Receivables of ₹0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Transgene Biotek and its competitors. Transgene Biotek's current Other Current Receivables is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.67, compared to a current price of ₹2.93 — trading 56.1% below its estimated fair value. The current Other Current Receivables is ₹0.00 Mil. Transgene Biotek's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current Other Current Receivables is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.93 is trading 56.1% below its estimated GF Value™ of ₹6.67. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Other Current Receivables: ₹0.00 Mil
  • GF Value™: ₹6.67 vs. price of ₹2.93 (56.1% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
45GF Score

Get the complete analysis for BOM:526139

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.93
Price
₹6.67
GF Value